Physician profile
Charles B Treasure
NPI 1306836531
$4,041.93
in general payments reported to CMS, 2019-2025
32 companies · $386 in 2025
The $386 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $619 · 2021: $310 · 2022: $742 · 2023: $598 · 2024: $976 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,756 · Travel and Lodging: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,756.05 |
| Travel and Lodging | $203.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,587.77 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $395.81 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $370.24 | 2021-2023 | Verquvo |
| Pfizer INC. | $309.15 | 2019-2025 | |
| Amgen INC. | $185.09 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $184.89 | 2019-2025 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $172.24 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $149.67 | 2020-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $135.39 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $85.51 | 2022-2023 | Lifevest |
| Atricure, INC. | $68.57 | 2024 | |
| Novo Nordisk INC | $64.54 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $39.90 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $39.37 | 2019 | |
| Daiichi Sankyo INC. | $35.32 | 2023 | Injectafer |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $34.04 | 2019-2023 | Opsumit, Uptravi |
| Amarin Pharma, INC. | $30.93 | 2021-2022 | |
| Abbott Laboratories | $24.33 | 2022 | |
| Irhythm Technologies, INC. | $23.02 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $22.90 | 2024 | Arcalyst |
| Teleflex LLC | $21.21 | 2025 | Vascband |
| Kiniksa Pharmaceuticals, LTD. | $19.43 | 2023 | Arcalyst |
| Angiodynamics, INC. | $15.12 | 2023 | Alphavac |
| Cardiovascular Systems INC. | $13.91 | 2019 | |
| Gilead Sciences, INC. | $13.58 | 2019 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Treasure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.